BackConduit Pharmaceuticals- Warrants (22/09/2028) Overview
Conduit Pharmaceuticals Inc - Warrants (22/09/2028)

Conduit Pharmaceuticals- Warrants (22/09/2028) Debt to Equity

Conduit Pharmaceuticals- Warrants (22/09/2028) (CDTTW) has a debt-to-equity ratio of 0.95, above the sector sector average of 0.2.

Get informed when a big investor buys or sells

+ Follow

Debt to Equity

0.95

Debt to Equity

0.95

Debt-to-Equity ratio measures a company's financial leverage by comparing its total debt to shareholder equity. A lower D/E ratio generally indicates a more financially stable company with less risk.

Debt to Equity (Comparison Companies)

Loading

Debt to Equity History

Loading

Debt to Equity Comparison

Loading

Conduit Pharmaceuticals- Warrants (22/09/2028) (CDTTW) FAQ

The latest debt-to-equity ratio for CDTTW is 0.95. That is above the sector sector average of 0.2. Investors often review this figure alongside Conduit Pharmaceuticals- Warrants (22/09/2028)'s historical trend and sector peers before judging valuation or financial health.

Against its sector companies, CDTTW currently prints 0.95 for debt-to-equity ratio, while the sector average sits near 0.2. That is roughly 375.9% above the sector mean. Large gaps often invite a closer look at Conduit Pharmaceuticals- Warrants (22/09/2028)'s growth, margins, and balance sheet.

A debt-to-equity ratio of 0.95 for Conduit Pharmaceuticals- Warrants (22/09/2028) is not 'good' or 'bad' on its own. Compare it with the peer average (0.2) and with CDTTW's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting CDTTW's debt-to-equity ratio (0.95), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.